- call +1-201-465-4211
- email sales@mrinsights.biz
Lysosomal storage diseases (LSDs) refer to a group of diseases arising because of the deficiency of lysosomal enzymes, which leads to the accumulation of partially digested or undigested macromolecules inside the cell.
Scope of the Report:
This report studies the Lysosomal Storage Diseases market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Lysosomal Storage Diseases market by product type and applications/end industries.
According to the report, one driver in the market is unmet medical needs.
The global Lysosomal Storage Diseases market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Lysosomal Storage Diseases.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Actelion Pharmaceuticals
BioMarin
Genzyme
Shire
Alexion Pharmaceuticals
Amicus Therapeutics
Chiesi Farmaceutici
Greenovation Biotech And FGK Clinical Research
Horizon Pharma
Leadiant Biosciences
Mylan
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Enzyme Replacement Therapy
Substrate Reduction Therapy
Cystine Depleting Agents
Market Segment by Applications, can be divided into
Hospitals
Ambulatory Surgical Centers
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Lysosomal Storage Diseases Market Overview
1.1 Product Overview and Scope of Lysosomal Storage Diseases
1.2 Classification of Lysosomal Storage Diseases by Types
1.2.1 Global Lysosomal Storage Diseases Revenue Comparison by Types (2017-2023)
1.2.2 Global Lysosomal Storage Diseases Revenue Market Share by Types in 2017
1.2.3 Enzyme Replacement Therapy
1.2.4 Substrate Reduction Therapy
1.2.5 Cystine Depleting Agents
1.3 Global Lysosomal Storage Diseases Market by Application
1.3.1 Global Lysosomal Storage Diseases Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.4 Global Lysosomal Storage Diseases Market by Regions
1.4.1 Global Lysosomal Storage Diseases Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Lysosomal Storage Diseases Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Lysosomal Storage Diseases Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Lysosomal Storage Diseases Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Lysosomal Storage Diseases Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Lysosomal Storage Diseases Status and Prospect (2013-2023)
1.5 Global Market Size of Lysosomal Storage Diseases (2013-2023)
2 Manufacturers Profiles
2.1 Actelion Pharmaceuticals
2.1.1 Business Overview
2.1.2 Lysosomal Storage Diseases Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Actelion Pharmaceuticals Lysosomal Storage Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.2 BioMarin
2.2.1 Business Overview
2.2.2 Lysosomal Storage Diseases Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 BioMarin Lysosomal Storage Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.3 Genzyme
2.3.1 Business Overview
2.3.2 Lysosomal Storage Diseases Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Genzyme Lysosomal Storage Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.4 Shire
2.4.1 Business Overview
2.4.2 Lysosomal Storage Diseases Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Shire Lysosomal Storage Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.5 Alexion Pharmaceuticals
2.5.1 Business Overview
2.5.2 Lysosomal Storage Diseases Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Alexion Pharmaceuticals Lysosomal Storage Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.6 Amicus Therapeutics
2.6.1 Business Overview
2.6.2 Lysosomal Storage Diseases Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Amicus Therapeutics Lysosomal Storage Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.7 Chiesi Farmaceutici
2.7.1 Business Overview
2.7.2 Lysosomal Storage Diseases Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Chiesi Farmaceutici Lysosomal Storage Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.8 Greenovation Biotech And FGK Clinical Research
2.8.1 Business Overview
2.8.2 Lysosomal Storage Diseases Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Greenovation Biotech And FGK Clinical Research Lysosomal Storage Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.9 Horizon Pharma
2.9.1 Business Overview
2.9.2 Lysosomal Storage Diseases Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Horizon Pharma Lysosomal Storage Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.10 Leadiant Biosciences
2.10.1 Business Overview
2.10.2 Lysosomal Storage Diseases Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Leadiant Biosciences Lysosomal Storage Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.11 Mylan
2.11.1 Business Overview
2.11.2 Lysosomal Storage Diseases Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Mylan Lysosomal Storage Diseases Revenue, Gross Margin and Market Share (2016-2017)
3 Global Lysosomal Storage Diseases Market Competition, by Players
3.1 Global Lysosomal Storage Diseases Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Lysosomal Storage Diseases Players Market Share
3.2.2 Top 10 Lysosomal Storage Diseases Players Market Share
3.3 Market Competition Trend
4 Global Lysosomal Storage Diseases Market Size by Regions
4.1 Global Lysosomal Storage Diseases Revenue and Market Share by Regions
4.2 North America Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
4.3 Europe Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
4.5 South America Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
5 North America Lysosomal Storage Diseases Revenue by Countries
5.1 North America Lysosomal Storage Diseases Revenue by Countries (2013-2018)
5.2 USA Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
5.3 Canada Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
5.4 Mexico Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
6 Europe Lysosomal Storage Diseases Revenue by Countries
6.1 Europe Lysosomal Storage Diseases Revenue by Countries (2013-2018)
6.2 Germany Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
6.3 UK Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
6.4 France Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
6.5 Russia Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
6.6 Italy Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Lysosomal Storage Diseases Revenue by Countries
7.1 Asia-Pacific Lysosomal Storage Diseases Revenue by Countries (2013-2018)
7.2 China Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
7.3 Japan Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
7.4 Korea Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
7.5 India Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
8 South America Lysosomal Storage Diseases Revenue by Countries
8.1 South America Lysosomal Storage Diseases Revenue by Countries (2013-2018)
8.2 Brazil Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
8.3 Argentina Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
8.4 Colombia Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Lysosomal Storage Diseases by Countries
9.1 Middle East and Africa Lysosomal Storage Diseases Revenue by Countries (2013-2018)
9.2 Saudi Arabia Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
9.3 UAE Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
9.4 Egypt Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
9.5 Nigeria Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
9.6 South Africa Lysosomal Storage Diseases Revenue and Growth Rate (2013-2018)
10 Global Lysosomal Storage Diseases Market Segment by Type
10.1 Global Lysosomal Storage Diseases Revenue and Market Share by Type (2013-2018)
10.2 Global Lysosomal Storage Diseases Market Forecast by Type (2018-2023)
10.3 Enzyme Replacement Therapy Revenue Growth Rate (2013-2023)
10.4 Substrate Reduction Therapy Revenue Growth Rate (2013-2023)
10.5 Cystine Depleting Agents Revenue Growth Rate (2013-2023)
11 Global Lysosomal Storage Diseases Market Segment by Application
11.1 Global Lysosomal Storage Diseases Revenue Market Share by Application (2013-2018)
11.2 Lysosomal Storage Diseases Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Ambulatory Surgical Centers Revenue Growth (2013-2018)
12 Global Lysosomal Storage Diseases Market Size Forecast (2018-2023)
12.1 Global Lysosomal Storage Diseases Market Size Forecast (2018-2023)
12.2 Global Lysosomal Storage Diseases Market Forecast by Regions (2018-2023)
12.3 North America Lysosomal Storage Diseases Revenue Market Forecast (2018-2023)
12.4 Europe Lysosomal Storage Diseases Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Lysosomal Storage Diseases Revenue Market Forecast (2018-2023)
12.6 South America Lysosomal Storage Diseases Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Lysosomal Storage Diseases Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Lysosomal Storage Diseases Picture
Table Product Specifications of Lysosomal Storage Diseases
Table Global Lysosomal Storage Diseases and Revenue (Million USD) Marke
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
